Physician profile
Pedro E Colton
NPI 1104001270
$12,211.45
in general payments reported to CMS, 2019-2025
30 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,146 · 2020: $1,004 · 2021: $817 · 2022: $1,377 · 2023: $1,692 · 2024: $2,625 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,789 · Education: $78.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,789.05 |
| Education | $78.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,302.96 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $993.22 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $912.75 | 2019-2024 | Xarelto |
| Mallinckrodt Hospital Products INC. | $894.71 | 2020-2025 | Acthar, Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $634.63 | 2019-2023 | Eliquis |
| Amgen INC. | $566.19 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Bayer Puerto Rico INC. | $542.87 | 2023-2025 | Kerendia |
| Travere Therapeutics, INC. | $493.07 | 2023-2025 | Filspari |
| Glaxosmithkline, LLC. | $477.93 | 2022-2025 | Benlysta |
| Horizon Therapeutics Plc | $451.04 | 2019-2023 | Krystexxa |
| Fennec Pharmaceuticals, INC. | $428.80 | 2024 | Pedmark |
| Mallinckrodt Enterprises LLC | $314.90 | 2019 | |
| Ani Pharmaceuticals, INC. | $296.38 | 2024-2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $293.76 | 2024-2025 | Watchman Flx, Avvigo Guidance System, Greenlight Xps |
| Vifor Pharma, INC. | $289.15 | 2019-2025 | Veltassa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $280.27 | 2019-2022 | |
| Medtronic, INC. | $274.02 | 2023-2024 | Ellipsys Vascular Access System, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.85 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $258.17 | 2019 | |
| Calliditas Therapeutics US INC. | $257.27 | 2024-2025 | Tarpeyo |
| Abbvie INC. | $199.55 | 2019-2020 | |
| Kyowa Kirin, INC. | $148.52 | 2024 | Crysvita |
| Novartis Pharmaceuticals Corporation | $135.72 | 2025 | |
| Scpharmaceuticals INC. | $124.95 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $118.71 | 2023 | Jynarque |
| Pfizer INC. | $68.81 | 2019 | |
| Fresenius USA Marketing, INC. | $59.57 | 2019 | |
| Abbott Laboratories | $58.93 | 2019 | |
| Pbg Puerto Rico LLC | $42.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Colton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.